PhaseV

Executive Summary

PhaseV is a Boston-based clinical research technology company founded in 2018 that leverages AI and machine learning to optimize clinical trial design, operations, and analysis. Its software platform enables biopharmaceutical sponsors and contract research organizations (CROs) to simulate trial outcomes, reduce costs, accelerate timelines, and improve the probability of success. Positioned at the intersection of biostatistics and AI, PhaseV addresses a critical pain point in drug development where nearly 90% of clinical trials fail to meet their original endpoints. The company's platform is designed to be agnostic to therapeutic area and trial phase, allowing broad applicability across the drug development spectrum. Despite being in a competitive landscape with players like Medidata and IQVIA, PhaseV's focus on real-time adaptive trial design and Bayesian statistics offers a differentiated value proposition. With the clinical trial software market expected to grow at over 12% CAGR through 2030, PhaseV is well-positioned to capture share as sponsors increasingly seek data-driven solutions to de-risk development programs. PhaseV is currently operating in a growth phase, having likely completed initial product validation and early customer engagements. The company's private status suggests it may be preparing for a Series A or B fundraising round to scale commercial operations and expand its engineering and sales teams. Based on available information, PhaseV appears to have a solid technological foundation but limited disclosed traction, resulting in a moderate conviction score. Key near-term events to watch include potential partnerships with top pharma companies and CROs, which would validate the platform's utility, as well as the release of new product features. Given the lack of detailed pipeline disclosures, the upcoming catalysts are inferred from typical milestones for private clinical trial software companies.

Upcoming Catalysts (preview)

• Q2 2026Major Partnership with Top Pharma or CRO60% success
• Q3 2026Series A or B Funding Round50% success
• Q4 2026Product Launch of Adaptive Trial Design Module40% success